Compare DexCom, Inc. (DXCM) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

HPE stock declined 8.45% to $45.37 amid a broader AI hardware sector pullback, though technical indicators remain bullish with strong support at $45. The company shows solid fundamentals with three consecutive earnings beats and robust AI infrastructure demand driving a record $6B backlog. Revenue grew to $34.3B in 2025 while maintaining a 33.9% gross margin, though net income dropped significantly to $57M due to acquisition-related costs.

HPE presents a compelling opportunity with analyst consensus target of $69.69 (54% upside) and strong AI infrastructure positioning, but faces execution risks from the Juniper integration and volatile cash flow trends. The stock's current valuation at 44.29 P/E appears elevated relative to historical norms, requiring careful monitoring of margin expansion and debt management.